What is Sihuan Pharmaceutical Holdings Group 3-Year ROIIC %?
Sihuan Pharmaceutical Holdings GroupSHPHF 52 3-Year ROIIC % is 364.62 as of Dec. 2025, which is 858% above its 10-year median of 38.05. GuruFocus rates SHPHF with a GF Score™ of 52/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 944 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 96.61% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sihuan Pharmaceutical Holdings Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 364.62%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHPHF's 3-Year ROIIC % is ranked better than 96.61% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs SHPHF: 364.62
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sihuan Pharmaceutical Holdings Group 3-Year ROIIC % Related Terms
Sihuan Pharmaceutical Holdings Group 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group 3-Year ROIIC % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 23.672292 (Dec. 2025) - -79.494 (Dec. 2022) )
/
( 983.521 (Dec. 2025) - 954.651 (Dec. 2022) )
=
103.166292
/
28.87
=
357.35%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a 3-Year ROIIC % of 364.62 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 858% above median its historical median of 38.05. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #32 out of 944 companies in the Drug Manufacturers industry, placing it in the top 3.4%.
Is Sihuan Pharmaceutical Holdings Group's 3-Year ROIIC % too high?
Sihuan Pharmaceutical Holdings Group's current 3-Year ROIIC % of 364.62 is 858% above median its 10-year median of 38.05. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Sihuan Pharmaceutical Holdings Group's value of 364.62 is 9701.6% above this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #32 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #32 out of 944 companies for 3-Year ROIIC %. This places Sihuan Pharmaceutical Holdings Group in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Sihuan Pharmaceutical Holdings Group's value of 364.62 is 9701.6% above this benchmark. While the company's 10-year median is 38.05 vs. the industry median of 3.72, Sihuan Pharmaceutical Holdings Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current 3-Year ROIIC % of 364.62 is 9701.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current 3-Year ROIIC % is 364.62, which is 858% above median its own 10-year median of 38.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.13 — trading 13.5% below its estimated fair value. The current 3-Year ROIIC % is 364.62, which is 858% above median its 10-year median of 38.05 and 9701.6% above the Drug Manufacturers industry median of 3.72. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current 3-Year ROIIC % is 364.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.13 is trading 13.5% below its estimated GF Value™ of $0.15.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
3-Year ROIIC %: 364.62 (858% above median its 10-year median of 38.05)
GF Value™: $0.15 vs. price of $0.13 (13.5% below fair value)
Industry Position: 9701.6% above the Drug Manufacturers median (#32 of 944)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score
Get the complete analysis for SHPHF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
